Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:50:45.059Z.
Calculation as of: 2026-10-06T18:50:45.059Z.
Quote observation: 2026-10-06T18:49:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9d3bab38235a1653807ee573cee89b2588007a5210257548b702658f8274e90
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
BioRestorative Therapies, Inc.
Market Cap
$3.10M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| BioRestorative Therapies, Inc. (BRTX) | $3.10M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.18M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.21M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.03M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.24M | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $2.97M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.28M | N/A |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.77M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.72M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.46M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
